Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

3 years ago

BMF-500, a novel 3rd generation covalent inhibitor of fms-like tyrosine kinase 3 (FLT3), is the second investigational compound, discovered and…

CorMedix Inc. Announces Notice of Allowance for U.S. Patent Application Covering Lead Product DefenCath

3 years ago

BERKELEY HEIGHTS, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

Goodness Growth Holdings Closes on Initial $2.0 Million Tranche of $10.0 Million Financing Commitment

3 years ago

MINNEAPOLIS, May 01, 2023 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF),…

Zymeworks Announces Participation in Upcoming Investor Conferences

3 years ago

VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional…

Nanox Files 2022 Annual Report on Form 20-F

3 years ago

NEVE ILAN, Israel, May 01, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical…

Financial Results and Business Update Conference Call to be Held May 2023 in Conjunction with 20-F Filing

3 years ago

MIAMI and BARRANQUILLA, Colombia, May 01, 2023 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a…

Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report

3 years ago

CORAL GABLES, Fla., May 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused…

Ring Therapeutics Strengthens Executive Team with Appointment of Christopher McNulty as Chief Financial Officer, Head of Corporate Strategy

3 years ago

McNulty brings deep experience in capital formation and business development to Ring Follows recent appointment of Dr. Christopher Wright as…

Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference

3 years ago

WALTHAM, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to…